Kliniken & Institute ... Kliniken Zentrum für Innere... Innere Medizin V:... Behandlungsspektrum ... Hämatologie Leukämien Publikationen

Ausgewählte Publikationen

AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia.

F Zhou, Y Liu, C Rohde, C Pauli, D Gerloff, M Köhn, D Misiak, N Bäumer, C Cui, S Göllner, T Oellerich, H Serve, MP Garcia-Cuellar, R Slany, JP Maciejewski, B Przychodzen, B Seliger, HU Klein, C Bartenhagen, WE Berdel, M Dugas, MM Taketo, D Farouq, S Schwartz, A Regev, J Hébert, G Sauvageau, C Pabst, S Hüttelmaier, C Müller-Tidow

Nat Cell Biol. 2017 Jul;19(7):844-855

 

DDX41-related myeloid neoplasia.

JP Maciejewski, RA Padgett, AL Brown, C Müller-Tidow

Semin Hematol. 2017 Apr;54(2):94-97

 

Inhibition of EZH2 degradation as a novel approach to overcome drug resistance in acute myeloid leukemia.

S Göllner, C Müller-Tidow

Mol Cell Oncol. 2017 Feb 15;4(2):e1291396

 

Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.

S Göllner, T Oellerich, S Agrawal-Singh, T Schenk, HU Klein, C Rohde, C Pabst, T Sauer, M Lerdrup, S Tavor, F Stölzel, S Herold, G Ehninger, G Köhler, KT Pan, H Urlaub, H Serve, M Dugas, K Spiekermann, B Vick, I Jeremias, WE Berdel, K Hansen, A Zelent, C Wickenhauser, LP Müller, C Thiede, C Müller-Tidow

Nat Med. 2017 Jan;23(1):69-78

 

Mesenchymal stromal cells contribute to quiescence of therapy-resistant leukemic cells in acute myeloid leukemia.

W Wang, T Bochtler, P Wuchter, L Manta, H He, V Eckstein, AD Ho, C Lutz

Eur J Haematol. 2017 Nov;99(5):392-398. 

 

Reduced hematopoietic stem cell frequency predicts outcome in acute myeloid leukemia.

W Wang, T Stiehl, S Raffel, VT Hoang, I Hoffmann, L Poisa-Beiro, BR Saeed, R Blume, L Manta, V Eckstein, T Bochtler, P Wuchter, M Essers, A Jauch, A Trumpp, A Marciniak-Czochra, AD Ho AD, C Lutz 

Haematologica. 2017 Sep;102(9):1567-1577

 

BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.

S Raffel, M Falcone, N Kneisel, J Hansson, W Wang, C Lutz, L Bullinger, G Poschet, Y Nonnenmacher, A Barnert, C Bahr, P Zeisberger, A Przybylla, M Sohn, M Tönjes, A Erez, L Adler, P Jensen, C Scholl, S Fröhling, S Cocciardi, P Wuchter, C Thiede, A Flörcken, J Westermann, G Ehninger, P Lichter, K Hiller, R Hell, C Herrmann, AD Ho, J Krijgsveld, B Radlwimmer, A Trumpp 

Nature. 2017 Nov 16;551(7680):384-388. 

 

Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients.

S Kayser, M Feszler, J Krzykalla, M Schick, M Kramer, A Benner, F Thol, U Platzbecker, C Müller-Tidow, AD Ho, G Ehninger, M Heuser, RF Schlenk, C Thiede, C Röllig, A Krämer 

Eur J Haematol. 2017 Dec;99(6):544-552

 

Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.

S Kayser, J Krzykalla, MA Elliott, K Norsworthy, P Gonzales, RK Hills, MR Baer, Z Ráčil, J Mayer, J Novak, P Žák, T Szotkowski, D Grimwade, NH Russell, RB Walter, EH Estey, J Westermann, M Görner, A Benner, A Krämer, BD Smith, AK Burnett, C Thiede, C Röllig, AD Ho, G Ehninger, RF Schlenk, MS Tallman, MJ Levis, U Platzbecker

Leukemia. 2017 Nov;31(11):2347-2354. doi: 10.1038/leu.2017.92. Epub 2017 Mar 21

 

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.

A Chaturvedi, L Herbst, S Pusch, L Klett, R Goparaju, D Stichel, S Kaulfuss, O Panknin, K Zimmermann, L Toschi, R Neuhaus, A Haegebarth, H Rehwinkel, H Hess-Stumpp, M Bauser, T Bochtler, EA Struys, A Sharma, A Bakkali, R Geffers, MM Araujo-Cruz, F Thol, R Gabdoulline, A Ganser, AD Ho, A von Deimling, K Rippe, M. Heuser, A. Krämer 

Leukemia. 2017 Oct;31(10):2020-2028. doi: 10.1038/leu.2017.46

 

Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia.

T Bochtler, M Granzow, F Stölzel, C Kunz, B Mohr, M Kartal-Kaess, K Hinderhofer, CE Heilig, M Kramer, C Thiede, V Endris, M Kirchner, A Stenzinger, A Benner, M Bornhäuser, G Ehninger, AD Ho, A Jauch, Krämer A; Study Alliance Leukemia Investigators.

Blood. 2017 Mar 9;129(10):1333-1342. 

 

Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia.

T Bochtler, S Fröhling, W Weichert, V Endris, C Thiede, B Hutter, M Hundemer, AD Ho, A Krämer 

Cold Spring Harb Mol Case Stud. 2016 Sep;2(5):a001123

 

Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.

S Kayser, A Benner, C Thiede, U Martens, J Huber, P Stadtherr, JW Janssen, C Röllig, MJ Uppenkamp, T Bochtler, U Hegenbart, G Ehninger, AD Ho, P Dreger, A Krämer 

Blood Cancer J. 2016 Jul 29;6(7):e449

 

Karyotype complexity and prognosis in acute myeloid leukemia.

F Stölzel, B Mohr, M Kramer, U Oelschlägel, T Bochtler, WE Berdel, M Kaufmann, CD Baldus, K Schäfer-Eckart, R Stuhlmann, H Einsele, SW Krause, H Serve, M Hänel, R Herbst, A Neubauer, K Sohlbach, J Mayer, JM Middeke, U Platzbecker, M Schaich, A Krämer, C Röllig, J Schetelig, M Bornhäuser, G Ehninger

Blood Cancer J. 2016 Jan 15;6:e386. 


Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia.

J Balss, C Thiede, T Bochtler, JG Okun, M Saadati, A Benner, S Pusch, G Ehninger, M Schaich, AD Ho, A von Deimling, A Krämer, CE Heilig

Leukemia. 2016 Apr;30(4):782-8


Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.

AD Ho, J Schetelig, T Bochtler, M Schaich, K Schäfer-Eckart, M Hänel, W Rösler, H Einsele, M Kaufmann, H Serve, WE Berdel, M Stelljes, J Mayer, A Reichle, CD Baldus, N Schmitz, M Kramer, C Röllig, M Bornhäuser, C Thiede, G Ehninger; Study Alliance Leukemia.Biol Blood Marrow Transplant. 2016 Mar;22(3):462-9.


Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia.

T Bochtler, S Fröhling, A Krämer

Leukemia. 2015 Jun;29(6):1243-52. 


Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.

C Röllig, H Serve, A Hüttmann, R Noppeney, C Müller-Tidow, U Krug, CD Baldus, CH Brandts, V Kunzmann, H Einsele, A Krämer, K Schäfer-Eckart, A Neubauer, A Burchert, A Giagounidis, SW Krause, A Mackensen, W Aulitzky, R Herbst, M Hänel, A Kiani, N Frickhofen, J Kullmer, U Kaiser, H Link, T Geer, A Reichle, C Junghanß, R Repp, F Heits, H Dürk, J Hase, IM Klut, T Illmer, M Bornhäuser, M Schaich, S Parmentier, M Görner, C Thiede, M von Bonin, J Schetelig, M Kramer, WE Berdel, G Ehninger; Study Alliance Leukaemia.
Lancet Oncol. 2015 Dec;16(16):1691-9


Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.

C Röllig C, M Bornhäuser, M Kramer, C Thiede, AD Ho, A Krämer, K Schäfer-Eckart, H Wandt, M Hänel, H Einsele, WE Aulitzky, N Schmitz, WE Berdel, M Stelljes, C Müller-Tidow, U Krug, U Platzbecker, M Wermke, CD Baldus, SW Krause, F Stölzel, M von Bonin, M Schaich, H Serve, J Schetelig, G Ehninger 

J Clin Oncol. 2015 Feb 10;33(5):403-10 


Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial.

J Schetelig, M Schaich, K Schäfer-Eckart, M Hänel, WE Aulitzky, H Einsele, N Schmitz, W Rösler, M Stelljes, CD Baldus, AD Ho, A Neubauer, H Serve, J Mayer, WE Berdel, B Mohr, U Oelschlägel, S Parmentier, C Röllig, M Kramer, U Platzbecker, T Illmer, C Thiede, M Bornhäuser, G Ehninger; Study Alliance Leukemia.

Leukemia. 2015 May;29(5):1060-8. 



Two cycles of risk-adapted consolidation therapy in patients with acute promyelocytic leukemia. Results from the SAL-AIDA2000 trial.

C Röllig, K Schäfer-Eckardt, M Hänel, M Kramer, M Schaich, C Thiede, U Oelschlägel, B Mohr, T Wagner, H Einsele, SW Krause, H Bodenstein, S Martin, R Stuhlmann, AD Ho, M Bornhäuser, G Ehninger, U Schuler, U Platzbecker 

Ann Hematol. 2015 Apr;94(4):557-63


Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts-a retrospective single-center experience.

A Radujkovic, S Dietrich, T Bochtler, A Krämer, T Schöning, AD Ho, P Dreger, T Luft

Eur J Haematol. 2014 Aug;93(2):112-7


Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.

JM Middeke, M Fang, JJ Cornelissen, B Mohr, FR Appelbaum, M Stadler, J Sanz, H Baurmann, G Bug, K Schäfer-Eckart, U Hegenbart, T Bochtler, C Röllig, F Stölzel, RB Walter, G Ehninger, M Bornhäuser, B Löwenberg, J Schetelig

Blood. 2014 May 8;123(19):2960-7


Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukemia.

T Bochtler, F Stölzel, CE Heilig, C Kunz, B Mohr, A Jauch, JW Janssen, M Kramer, A Benner, M Bornhäuser, AD Ho, G Ehninger, M Schaich, A Krämer 

J Clin Oncol. 2013 Nov 1;31(31):3898-905


Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).

S Amadori, S Suciu, R Stasi, HR Salih, D Selleslag, P Muus, P De Fabritiis, A Venditti, AD Ho, M Lübbert, X Thomas, R Latagliata, CJ Halkes, F Falzetti, D Magro, JE Guimaraes, Z Berneman, G Specchia, M Karrasch, P Fazi, M Vignetti, R Willemze, T de Witte, JP Marie

J Clin Oncol. 2013 Dec 10;31(35):4424-30


High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.

M Schaich, S Parmentier, M Kramer, T Illmer, F Stölzel, C Röllig, C Thiede, M Hänel, K Schäfer-Eckart, W Aulitzky, H Einsele, AD Ho, H Serve, WE Berdel, J Mayer, N Schmitz, SW Krause, A Neubauer, CD Baldus, J Schetelig, M Bornhäuser, G Ehninger 

J Clin Oncol. 2013 Jun 10;31(17):2094-102


Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.

H Serve, U Krug, R Wagner, MC Sauerland, A Heinecke, U Brunnberg, M Schaich, O Ottmann, J Duyster, H Wandt, T Fischer, A Giagounidis, A Neubauer, A Reichle, W Aulitzky, R Noppeney, I Blau, V Kunzmann, R Stuhlmann, A Krämer, KA Kreuzer, C Brandts, B Steffen, C Thiede, C Müller-Tidow, G Ehninger, WE Berdel 

 

J Clin Oncol. 2013 Sep 1;31(25):3110-8